Manufacturer record

ZRS Pharmaceuticals India Pvt. Ltd: regulatory record

Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories

7 batches manufactured by ZRS Pharmaceuticals India Pvt. Ltd (Himachal Pradesh) were declared Not of Standard Quality between January 2025 and June 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.

Records by type

7 records linked to ZRS Pharmaceuticals India Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.

0Banned or prohibited
0Recalled or suspended
7Failed a lab test
0Regulatory notice
Primary government sourceTier 1: government primary source

CDSCO drug alerts: Not of Standard Quality and spurious drugs

CDSCO · CDSCO monthly NSQ alerts, Jan 2025 to Jun 2026

View original document

Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.

7
NSQ batches since 2025
7
Products affected
Assay
Most common failure
Jun 2026
Latest alert

Flagged batches per year

2025 · 32026 · 4

All flagged batches

Product Batch Reason declared NSQ Tested by Alert
Esomeprazole Tablets IP ZRST-3430Mfg 2026-02 · Exp 2028-01 Sample does not conform to IP Standards. If fails the tests Assay and Dissolution as per IPAssay DTL, TVMState lab Jun 2026
PIRACETAM SYRUP ZRSL1085Mfg 2024-11 · Exp 2026-10 Misbranded-Incorrect LabellingMisbranded DTL, PuducherryState lab Mar 2026
Ofloxacin, Metronidazole & Simethicone Suspension ZRSL - 1533Mfg 2025-06 · Exp 2027-05 The sample does not conform to claim as per Patent and Proprietary in respect to the Assay of Ofloxacin.Assay RDTL, ChandigarhCDSCO lab Jan 2026
Diphenhydramine HCl, Ammonium Chloride, Sodium Citrate & Menthol Syrup ZRSL - 1806Mfg 2025-09 · Exp 2027-08 The sample does not conform to claim as per Patent and Proprietary in respect to the Assay of Sodium Citrate and Menthol.Assay RDTL, ChandigarhCDSCO lab Jan 2026
Prednisolone Tablets IP 20mg(Prednimeg-20) ZRST-2403Mfg 2025-05 · Exp 2027-04 Incorrect labellingLabelling DTL, PuducherryState lab Dec 2025
Coxmyth-60 Tablets, (Etoricoxib Tablets IP 60mg) ZRST-1325Mfg 2024-07 · Exp 2026-06 Assay for EtoricoxibAssay State Lab KarnatakaState lab Jun 2025
Thiamine Hydrochlori de Tablets IP 100mg (KTHAMINE -100) ZRST- 1361Mfg 2024-08 · Exp 2026-01 (i) On the received sample, Presence of Spot defect was observed which should not be present as per DCC Guidelines on Not Of Standard Quality (NSQ) Drugs Approved in 1993 (Annexure A) Tablets vide serial No.(i) Presence of Spot/discoloration. (ii)The label of the container in the drug is mentioned as 'Approved colour used' but the common name of the permitted colour used in the formulation as prescribed under rule 127 (2) of the drug rule was not mentioned. (iii) The label claim of the drug states 'Thiamin hydrochloride IP 100mg' instead of ' Thiamine Hydrochoride IP 100mg' but the proper name of the drug should be written as prescribed under 96(1),(i)(A) of The Drugs and Cosmetics Act. (iv) The label claim of the received sample states Thiamin Hydrochloride IP 100mg whereas in the IP monograph, The usual strength of the thiamine tablet is stated as 5mg, 10mg, 50mg. Hence,the Strength of the sample received does not match the usual strength as mentioned in the IP monograph. - NSQLabelling State Lab PuducherryState lab Jan 2025

Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.